Literature DB >> 23358691

Is survivin expression prognostic or predictive in malignant pleural mesothelioma?

Julija Hmeljak1, Nina Erčulj, Vita Dolžan, Jože Pižem, Izidor Kern, Viljem Kovač, Maja Cemažar, Andrej Cör.   

Abstract

Malignant pleural mesothelioma is an incurable cancer strongly associated with asbestos exposure and characterised by poor response to treatment. The inhibitor-of-apoptosis protein family member survivin is involved in apoptosis and proliferation and is expressed in cancer cells only. The aims of the present study were to elucidate whether survivin expression is associated with tumour cell apoptosis and proliferation and to assess the prognostic and predictive value of survivin expression in malignant pleural mesothelioma. Archival pleural mesothelioma tissue samples from 101 patients were immunohistochemically analysed for nuclear expression of survivin, for proliferation with the use of Ki-67 as marker and for apoptosis using active caspase-3 as a marker. Staining results and clinical data were included in a survival analysis. Survivin was highly expressed in tumour cell nuclei in all samples and this correlated positively with both apoptosis and proliferation, but did not have a significant prognostic value. We found significantly higher survivin expression in patients who responded to chemotherapy compared to patients with progressive disease. Survivin expression might contribute to treatment response prediction, but survivin expression in malignant pleural mesothelioma did not have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358691     DOI: 10.1007/s00428-013-1373-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

Review 1.  Mesothelial cell proliferation and apoptosis.

Authors:  Lorriana E Leard; V Courtney Broaddus
Journal:  Respirology       Date:  2004-08       Impact factor: 6.424

Review 2.  Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I.

Authors:  R A Walker
Journal:  Histopathology       Date:  2006-10       Impact factor: 5.087

3.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.

Authors:  Takehiko Dohi; Fang Xia; Dario C Altieri
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

4.  Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma.

Authors:  S Donoghue; H S Baden; I Lauder; S Sobolewski; J H Pringle
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan.

Authors:  Shuko Nojiri; Kenichi Gemba; Keisuke Aoe; Katsuya Kato; Takuhiro Yamaguchi; Tsugumichi Sato; Kiyoshi Kubota; Takumi Kishimoto
Journal:  Jpn J Clin Oncol       Date:  2010-08-26       Impact factor: 3.019

6.  Eighth international mesothelioma interest group.

Authors:  M Carbone; S M Albelda; V C Broaddus; R M Flores; G Hillerdal; M-C Jaurand; K Kjaerheim; H I Pass; B Robinson; A Tsao
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

7.  Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.

Authors:  Kwang Woon Kim; Robert W Mutter; Christopher D Willey; Ty K Subhawong; Eric T Shinohara; Jeffrey M Albert; Geng Ling; Carolyn Cao; Young Jin Gi; Bo Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-01       Impact factor: 7.038

Review 8.  New wirings in the survivin networks.

Authors:  D C Altieri
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

Review 9.  The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer.

Authors:  Boaz Nachmias; Yaqoub Ashhab; Dina Ben-Yehuda
Journal:  Semin Cancer Biol       Date:  2004-08       Impact factor: 15.707

Review 10.  Malignant mesothelioma.

Authors:  Alastair J Moore; Robert J Parker; John Wiggins
Journal:  Orphanet J Rare Dis       Date:  2008-12-19       Impact factor: 4.123

View more
  7 in total

Review 1.  Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

Authors:  Elisa Barone; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

3.  Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.

Authors:  Mayura Meerang; Karima Bérard; Martina Friess; Byron K Y Bitanihirwe; Alex Soltermann; Bart Vrugt; Emanuela Felley-Bosco; Raphael Bueno; William G Richards; Burkhardt Seifert; Rolf Stahel; Walter Weder; Isabelle Opitz
Journal:  Mol Oncol       Date:  2016-06-25       Impact factor: 6.603

4.  Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia.

Authors:  Kei Kushitani; Vishwa Jeet Amatya; Amany Sayed Mawas; Rui Suzuki; Yoshihiro Miyata; Morihito Okada; Kouki Inai; Takumi Kishimoto; Yukio Takeshima
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

5.  Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma.

Authors:  Guozun Zhang; Dong-Liang Yang; Guoqi Zheng; Yufei Liang
Journal:  Oncol Lett       Date:  2020-04-02       Impact factor: 2.967

6.  Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.

Authors:  Sarah Adel Hakim; Hoda Hassan Abou Gabal
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

7.  Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma.

Authors:  Katja Goričar; Viljem Kovač; Alenka Franko; Metoda Dodič-Fikfak; Vita Dolžan
Journal:  Dis Markers       Date:  2015-09-16       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.